Literature DB >> 6489413

Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.

D Sommariva, D Bonfiglioli, I Pogliaghi, C Ottomano, A Fasoli.   

Abstract

Twenty five hypertriglyceridaemic patients (16 Type IV and 9 Type IIb) were treated with fenofibrate 300 mg/d. In Type IV patients serum triglycerides and VLDL cholesterol decreased, while LDL and HDL cholesterol rose significantly. In Type IIb patients, triglycerides and total, VLDL, IDL and LDL cholesterol were significantly reduced by the treatment. The correction of hypertriglyceridaemia by fenofibrate seems, therefore, to induce different changes in lipoproteins in Type IIb and in Type IV hyperlipoproteinaemic patients. The practical implications of these results are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6489413     DOI: 10.1007/bf00541935

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  THE FATE OF PLASMA FREE FATTY ACIDS AND THEIR EFFECTS ON TISSUE METABOLISM.

Authors:  D STEINBERG
Journal:  Metabolism       Date:  1964-10       Impact factor: 8.694

2.  Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study.

Authors:  L A Carlson; L E Böttiger
Journal:  Lancet       Date:  1972-04-22       Impact factor: 79.321

Review 3.  Classification of hyperlipidaemias and hyperlipoproteinaemias.

Authors:  J L Beaumont; L A Carlson; G R Cooper; Z Fejfar; D S Fredrickson; T Strasser
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

4.  Treatment of hyperlipidemic states.

Authors:  E H Strisower; G Adamson; B Strisower
Journal:  Med Clin North Am       Date:  1970-11       Impact factor: 5.456

5.  Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease.

Authors:  G J Miller; N E Miller
Journal:  Lancet       Date:  1975-01-04       Impact factor: 79.321

6.  Relationship between plasma lipid concentrations and coronary artery disease in 496 patients.

Authors:  A M Gotto; G A Gorry; J R Thompson; J S Cole; R Trost; D Yeshurun; M E DeBakey
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

Review 7.  Hypertriglyceridemia: mechanisms, clinical significance, and treatment.

Authors:  S M Grundy
Journal:  Med Clin North Am       Date:  1982-03       Impact factor: 5.456

8.  Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs.

Authors:  G Franceschini; A Poli; A L Catapano; E Gatti; M Sirtori; G Gianfranceschi; C R Sirtori
Journal:  Atherosclerosis       Date:  1981 Nov-Dec       Impact factor: 5.162

9.  Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol.

Authors:  L A Carlson; L E Böttiger; P E Ahfeldt
Journal:  Acta Med Scand       Date:  1979

10.  [How does fenofibrate exert its cholesterol-lowering effect? (author's transl)].

Authors:  E Wülfert
Journal:  Nouv Presse Med       Date:  1980-12-22
View more
  3 in total

1.  Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.

Authors:  L Kłosiewicz-Latoszek; W B Szostak
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Over-the-counter fish oil use in a county hospital: Medication use evaluation and efficacy analysis.

Authors:  Amulya Tatachar; Margaret Pio; Denise Yeung; Elizabeth Moss; Diem Chow; Steven Boatright; Marissa Quinones; Annie Mathew; Jeffrey Hulstein; Beverley Adams-Huet; Zahid Ahmad
Journal:  J Clin Lipidol       Date:  2015-02-21       Impact factor: 4.766

3.  Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb.

Authors:  S Bertolini; N Elicio; A Daga; M L Degl'Innocenti; R Balestreri; M G Fusi; A M Cotta Ramusino; A Carozzi
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.